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Background: The origin of 40% of syncope remains unknown even after
a complete diagnostic work-up. Previous studies have suggested that ade-
nosine 5’-triphosphate (ATP) testing has value in selecting successful therapy.
This patient-blinded, multicenter, randomized superiority trial tested whether,
in patients with syncope of unknown origin (SUO), selecting cardiac pacing
in those with a positive ATP test results in fewer recurrences than those who
do not receive pacing.
Methods and Results: From 2000 to 2005, 80 consenting patients (mean
age 75.9±7.7 years; 81% women; 56% without diagnosed structural heart
disease) with syncope of unknown origin and atrioventricular or sinoatrial
block lasting longer than 10 seconds (average 17.9±6.8 seconds) under ATP
administration (20 mg IV bolus) were recruited from 10 hospitals, implanted
with programmable pacemakers and randomized to either active pacing (dual-
chamber pacing at 70 beats per minute (bpm) or backup pacing (atrial pacing
at 30 bpm). Patients were followed regularly for up to five years for any syn-
cope recurrence, the primary outcome.
Mean follow-up was 16 months. Syncope recurred in eight (21%) of
39 patients randomized to active pacing and in 27 (66%) of 41 randomized to
backup pacing (control), yielding a hazard ratio of 0.25 (95% CI: 0.12-0.56).
After recurrence, the 27 recurrent control patients were reprogrammed to
active pacing and only one reported subsequent syncope.
Conclusions: This study suggests that, in elderly patients with syncope of
unknown origin and positive ATP tests, active dual-chamber pacing reduces
syncope recurrence risk by 75% (95% confidence interval, 44-88).
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Background: Extracellular adenosine-5’-triphosphate (ATP) suppresses
cardiac pacemakers' automaticity and AV nodal conduction directly and indi-
rectly by adenosine and a triggered cardio-cardiac vagal reflex. This action
constitutes the rationale for the ATP-test, a diagnostic tools aimed to identify
patients with syncope of unknown origin (SUO) who could benefit from pace-
maker therapy. Two criteria have been used to determine a positive outcome
of the ATP test: (i) the duration of ATP-induced cardiac pause (CP) due to
AV nodal conduction block or suppressed sinus node, ignoring escape beats,
and (ii) the maximal RR interval irrespective of the origin of the QRS com-
plexes (RRmax). The test is deemed positive when CP is >10 sec or RRmax
>6 sec Two contrasting conclusions regarding the utility of the test have been
reached using these two criteria. The aim of the current post-hoc study, was
to explain the discrepancy between the two conclusions.
Methods: ATP test consists on an I.V. bolus injection of 20 mg of ATP
into an antecubital vein. We analyzed data of 33 patients-cohort derived from
a multicenter study having incorporated 80 SUO patients (Circulation
2012;125:31-6), in which the ATP-test was positive using the CP duration and
negative using the RRmax interval. The 47 remaining patients had both tests
positive and were excluded from this analysis.
Results: A dual chamber pacemaker was implanted in all 33 patients: in
14 and 19 patients the pacemaker was programmed for DDD70 bpm and
AAI30 bpm (control) pacing modes, respectively. Syncope recurred in only
one of the 14 DDD70 patients (7%) during a follow up period of 17.0±8.6
months, but in 10 of the 19 AAI30 patients (53%) during 5.3±5.2 months
(p<0.009).
Conclusion: This study shows that ATP-test is a useful diagnostic tool for
identifying patients with bradycardic syncope who might benefit from pacing
therapy when the CP criterion -and not the RRmax criterion- is used to deter-
mine the outcome of the test.
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Non valvular atrial fibrillation (NVAF) is associated with an increased risk
of stroke. CHADS2 score is used to guide thromboporphylaxis among patients
with NVAF. Copeptine a vasoactive peptide reflecting cardiac stress has been
recently evaluated in combination with Troponin to exclude the diagnosis of
acute coronary syndrome but had never been tested in atrial fibrillation. We
evaluated the relation between the CHADS2 score and several biomarkers
representing multiple pathways implicated in non valvular atrial fibrillation.
Methods: Plasma concentrations of Troponin I (TnI), BNP, mid-regional
proatrial natriuretic peptide (MR-proANP)), hs- CRP, D-dimer and mid-
copeptin (CT-proAVP)) were measured at the time of admission in 45 NVAF
consecutive patients. The association between the median values of these
markers, clinical characteristics, transthoracic echocardiographic parameters
and stroke risk stratification as assessed by the CHADS2 score was tested.
Results: Baseline patients characteristics were as follows: mean age was
64.6±14.9 years, 56% were men, 51% had hypertension, and 7% had diabetes. In
seven patients (16%) NVAF was associated with acute heart failure. Thirtheen
patients (29%) had a prior AF. NVAF was paroxysmal in 67% of patients Mean
LV EF was 54.3±15.7%.and mean LA surface was 21.6±7.1 cm².
Mean CHADS score was 1.1±1 
Table 1 depicted the level of each biomarkers according to the CHADS2
score ANP, Copeptine, hs-CRP, D-dimer levels were increased with the
increased of the CHADS2 score.
Conclusion: Copeptine levels were found to be higher in patients at higher
risk of thrombo embolism as assessed by CHADS2 score.
Table 1 – Results
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The management and prognosis of heart diseases (HD) or arrhythmias may
depend on the patient gender. The purpose of the study was to look for the
influence of gender on the indications and the long-term results of ablation of
atrial flutter (AFl).
Methods: 965 patients, 743 males, 222 females (23%), mean age 64±
12 years were consecutively referred for radiofrequency ablation of recurrent
CHADS2=0 CHADS2=1 CHADS2 >= 2
N=15
median (IQR)
n=14
median (IQR)
n=16
median (IQR) 
 
p
BNP (pg/ml) 244 
(96-378)
394.5 
(120-524)
433.5 
(248.5-644)
0,1422
ANP (pmol/l) 108.9 
(86.56-188.9)
257.2
(122.6-391.4)
305.05
(244.75-406.3)
0,0037
Troponin I (ng/ml) 0.04 
(0.04-0.04)
0.04 
(0.04-0.04)
0.04 
(0.04-0.06)
0,4919
Copeptine (pmol/l) 7.39 
(5-9.48)
8.005 
(5-17.21)
13.685 
(9.145-26.845)
0,0221
Hs CRP (mg/l) 3 (1.53-10) 4.085 (1.96-10) 10 (6.53-34.05) 0,0247
D – dimer (ng/ml) 267 (215-366) 682 (250-751) 816 (516-1055) 0,0346
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or poor-tolerated AFL Clinical history, other arrhythmias as atrial fibrillation
(AF), data of echocardiography were collected. The patients were followed
from 3 months up to 10 years.
Results: Women tended to be older than men (65.5±12 vs 64±11.5 years)
(p< 0.08). Underlying HD was as frequent in women as in men (76%). HD
nature differed: women had more congenital HD (10 vs 2%, p<0.0001), more
valvular HD (17.5 vs 10% p<0.002) and less respiratory failure (4.5 vs 10%)
(p<0.01), less ischemic HD (5 vs 20%)(p<0.0000) than men. Hypertensive HD,
dilated cardiomyopathy or various HD’s did not differ. Previous history of AF
was more frequent in women (31.5%) than in men (26%) (p<0.012). AFl-
related rhythmic cardiomyopathy tended to be less frequent in women than in
men (4 vs 8%) (p<0.07). Presentation with 1/1 AFl was as frequent in women
as in men (10% vs 7%). AFl ablation-related major complications as complete
AV block, death or cardiac shock were more frequent in women than in men
(4 vs 1%)(p<0.004). After 3±3 years, AFl recurrences tended to be less fre-
quent in women than in men (8.5 vs 13%)(p<0.06). AF occurrence was more
frequent in women than in men (24 vs 14%)(p<0.0002). Among these patients
66% of women and men had no history of AF before AFl ablation. Their risk
of AF remains higher in women than in men (16% vs 8%)(p<0.007).
Conclusions: There gender-related differences in the prevalence, clinical
presentation, ablation-related complications and AF incidence. AFL is less
common in women than in men, despite similar age and as frequent under-
lying HD. The risk of AFl ablation-related major complications is higher in
women than in men. Women have more frequently history of AF and an inde-
pendent higher risk than men of developing AF after ablation of atrial flutter.
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Introduction: Studies have documented the underuse of oral anticoagulant
therapy (OAC) as stroke prophylaxis in older persons with history of atrial
fibrillation (AF). Failure to prescribe OAC is often due to the perception by
physicians of bleeding because of specific older people clinical factors.
We performed a prospective observational study in the University Hospital
of Reims, whose aim was to evaluate the management of thromboembolic risk
in older patients in everyday-life hospital practice and impact of frailty and
dependence objective parameters.
Method: 150 AF patients over 75 years were consecutively included over
a period of four months. Clinical and biological data, risk scores for bleeding
(HASBLED) and thrombo-embolic events (CHADS and CHADSVASc) were
computed. Several scores and parameters of assessment of autonomy and risk
of falling were independently recorded: MMS (Mini-Mental Status), ADL
(Activities of Daily Living) and IADL (Instrumental ADL).
Results: Mean age was 83±13 years (75 men). At discharge, 52.2% of
patients were under OAC. Mean CHADS, CHADSVASc and HASBLED
score were respectively 2,6±0,1, 4,6±0,1 and 2,3±0,1; all patients had a CHA
DS VASc score ≥2 and 86% a CHADS ≥2. The HASBLED score was asso-
ciated with non-prescription of anticoagulation (p=0.001), while none of the
thrombo-embolic scores was significantly associated with prescription. Spe-
cific studied parameters are in table.
Conclusion: In our study of everyday practice, there is an underuse of anti-
coagulation in the elderly compared to guidelines, mainly because the percep-
tion of the hemorrhagic risk prevails over the thrombo-embolic risk. Specific
geriatric parameters could help to choose the appropriate therapy.
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Introduction: Age is a major thrombo-embolic risk factor in atrial fibril-
lation (AF), but also a risk factor for bleeding under oral anticoagulation
therapy (OAC). However, it appears that older patients are inadequately
treated with OAC.
The objective of our study was to evaluate the use of OAC in elderly
patients hospitalised in a cardiology department according to current guide-
lines.
Method: Over a 4-month period, 142 patients over 75 years old with his-
tory of AF were included. Clinical and biological data were recorded, and risk
scores for bleeding (HASBLED) and thrombo-embolic events (CHADS2 and
CHA2DS2VASc) were independently assessed after discharge. The differences
between bleeding and thrombo-embolic risk were calculated for each patient.
Patients with OAC at discharge and patients without OAC were compared.
Results: Mean age was 83±13 years (75 men). Mean CHADS, CHADS-
VASc and HASBLED scores were respectively 2,6±0,1, 4,6±0,1 and 2,3±0,1.
According to CHADSVASc score and guidelines all of the patients were
eligible for OAC. However 47.8% of patients were not under OAC. Those
patients were older (84.6±0.6 vs. 81.8±0.5; p=0.001), predominantly female
(66 vs. 35%; p=0.001) with a higher serum creatinine (127.3±7.3 vs. 106±6.3;
p=0.03) and HASBLED score (2.7 vs. 2.16; p=0.001). OAC use was not asso-
ciated with CHADS and CHADSVASc scores values.
Conclusion: Our study in daily pratice confirms that OAC in older patients
with AF are underused and that the bleeding risk may be over-rated and/or
thrombo-embolic risk under-estimated. However, specific risk factors in older
patients may not be included in currently used scores.
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Introduction: Characteristics of patients with atrial fibrillation (AF) are
well known, however the patients included in published studies are usually
younger than patients encountered in daily practice in hospital.
Anticoagulation
=74
o anticoagulation
=68
p
Age (years) 81.8±0.5 84.6±0.6 0.001
Creatinine (µmol/l) 106±7.3 127.3±6.3 0.03
Dependency (%) 27 54 0.001
Dementia (%) 4,1 14,7 0.04
High risk of falling (%) 0 20 0,001
MMS score 21.4±1.2 20.1±1.1 NS
ADL score 5.1±0.3 3.8±0.4 0.001
IADL score 2±0.2 2.4±0.4 NS
OAC o OAC
T (CHADS) >B 49.2% 39%*
T (CHADS) < B 2.3%µ 9.2%
T (CHADSVASC) >B  47%  40%*
T (CHADSVASC) < B 3.8%µ 8.4%
T: Thrombo-embolic risk; B: bleeding risk (HASBLED) according to scores
*: undertreated patients according to scores
µ: over-treated patients according to scores
